BioNukleo was founded in 2014 and is located at the chair of bioprocess engineering at Technische Universität Berlin.
BioNukleo is based on the chemo-enzymatic production of modified nucleosides and nucleotides. Nucleosides and their analogues are well known for their antiviral, antibacterial and anticancer activities. The multistep and highly expensive chemical synthesis process hinder their wide spread as therapeutic agents, as well as limiting their use in biological trials. Chemo-enzymatic methods are being used as the new approach for synthesis, due to their relatively low cost, high selectivity and being environmentally friendly.
Next generation nucleic acid derivative synthesis
Based on innovative and sustainable biochemical methods, we are performing customized synthesis with high regio- and stereoselectivity.
We are specialized:
- in the production of hard to synthesize biocatalysts
- in the utilization of the biocatalysts for the production of intermediates and final products like nucleoside, nucleotides and sugar-1-phosphates.